SEARCH · PubMed Health

Results for “Timolol”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 937 records · Page 52Linked to original sources

PubMed1980

Timolol-maintenance treatment.

Thirty-eight patients with ocular hypertension or glaucoma were treated with topical timolol for 12-30 months (mean 20). A long lasting hypotensive effect of timolol eyedrops was found. However a need to increase therapy during the follow-up period was noted especially in the glaucoma group. Eyes with pseudoexfoliations often required concomitant therapy from the beginning. Ocular side effects were relatively few but four cases of punctate keratitis and another two with decreased corneal sensitivity were observed.

Aged↗

PubMed1982

Timolol maleate in the treatment of glaucoma simplex and glaucoma capsulare. A three-year follow up study.

180 eyes of 97 patients with primary open angle glaucoma and IOP greater than 22 mm were treated for more than 3 years with timolol-maleate. 130 eyes had glaucoma simplex, and 50 eyes had glaucoma capsulare. With timolol maleate as the only medication after 3 years, the IOP was controlled in 33% of the glaucoma simplex group, and in 8% of the glaucoma capsulare group. No serious local or systemic side-effects were observed.

Aged↗

PubMed1982

Short term effects of timolol in chronic glaucoma. A double blind study using computerized perimetry.

15 patients with glaucomatous field defects in at least one eye were subjected to computerized perimetry and IOP, systemic blood pressure and pulse rate measurements before and after timolol or placebo instillation in both eyes. A significant decrease of IOP and pulse rate was found 2 h after timolol. The visual fields were not improved, the correlation between IOP and visual field performance being (though not significantly) positive. The lack of improvement could not be attributed to the decrease in pulse rate.

Aged↗

PubMed1986

Timolol and cornea.

The influence of timolol on the corneal epithelium and endothelium was studied in organ culture. The cell morphology was not influenced by drug concentrations less than or equal to 690 micrograms/ml. Cell death was observed at 6900 micrograms/ml. Endothelial cell proliferation after an experimental injury was slowed down at a drug concentration of 690 micrograms/ml. Injurious effects were not observed at the drug concentrations found in the aqueous humour by use of ophthalmic eye solution in eyes with a normal cornea. However, it may be indicated to use eye drops with reduced concentration of timolol in conditions facilitating the resorbtion of the drug.

Animals↗

PubMed1988

Comparison of topical timolol vs betaxolol on cardiopulmonary exercise performance in healthy volunteers.

The effects of topical timolol vs betaxolol on cardiopulmonary exercise performance were studied in a randomised double-masked fashion in 12 healthy male volunteers. Cardiopulmonary parameters were evaluated at the anaerobic threshold and at peak exercise. Intraocular pressure was determined before and after treatment by applanation tonometry. No differences were found in aerobic or peak exercise capacity. Maximal heart rate was slightly lower (P less than 0.05) following treatment with timolol compared with betaxolol. However, a correspondingly higher oxygen pulse (oxygen uptake/heart rate) compensated for this reduction and resulted in no difference in peak performance. At physiological work levels, it was not possible to demonstrate any influence of topical, selective or non-selective, beta-adrenergic blockade on cardiopulmonary exercise performance in these healthy volunteers.

Adrenergic beta-Antagonists↗

PubMed1980

Addition of timolol maleate to routine medical therapy: a clinical trial.

A double-blind cross-over trial of timolol maleate (Timoptol) while routine medical therapy was continued gave the result that pressure was reduced by 3.22 mmHg is compared to placebo and 5.01 compared to pre-timolol levels in 24 patients. There was also a small (1.858 mmHg) drop in pressure in placebo treated eyes, a small and statistically significant drop in resting pulse rate, 76.67 to 71.39/min, and a small but not statistically significant drop in diastolic blood pressure.

Adult↗

PubMed1981

Interaction of timolol and adrenaline.

In a prospective double-blind randomised trial the interaction of timolol and adrenaline was studied in 20 patients with open-angle glaucoma and exfoliative glaucoma. After pretreatment for at least 2 weeks with timolol eyedrops adrenaline was added in a double-blind manner, and the intraocular pressure was recorded during 4 days. The study showed a significantly additive hypotensive effect of adrenaline, which was more pronounced in patients with exfoliative glaucoma.

Clinical Trials as Topic↗

PubMed1983

Visual field survival: the response to timolol therapy in open-angle glaucoma.

A simple method for quantifying visual field survival was devised to assess the progress of chronic simple glaucoma in 36 patients treated with timolol maleate over a 3-year period. Routine tonometric monitoring of the intraocular pressure (IOP) was carried out in conjunction with these Goldmann field studies. Statistical analysis revealed that field survival measurement provided a more consistent clinical guide to the progress of glaucoma under treatment than did IOP (p much less than 0.001). Timolol therapy was associated with sustained IOP reductions of 24.3-34.5%, and 63% of those treated who were monitored for field survival showed no significant field loss. The observed relationships of IOP to field survival are discussed.

Aged↗

PubMed1985

Penetration of timolol eye drops into human aqueous humour: the first hour.

Samples of aqueous humour were removed from 26 eyes at the start of cataract extraction. Two drops of timolol 0.5% had been instilled into the conjunctival sac 12-71 minutes before operation. Analysis by gas chromatography showed a mean timolol concentration of 55.46 ng/mg, with a range of 8 to 100 ng/mg.

Aqueous Humor↗

PubMed1990

Topical timolol and serum lipoproteins.

Oral timolol taken for the treatment of systemic hypertension has been shown to affect adversely serum lipoprotein levels. In a 15-week study on 19 patients topical timolol therapy for raised intraocular pressure was found to have no significant adverse effect on serum lipoprotein levels. This is reassuring in view of the large number of patients on this form of long term therapy, and selection of the type of beta blocker to use should not be influenced by lipid changes associated with the oral form of the drug.

Administration, Topical↗

PubMed1978

Elevated vascular reactivity in the timolol-treated spontaneously hypertensive rat.

Spontaneously hypertensive rats (SHR) treated in utero with a low dose, and from weaning with 6 mg/kg per day of oral timolol, a noncardioselective beta-adrenergic blocker, did not develop hypertension. Isolated aortic rings from these animals showed increased reactivity to raised extracellular K+, when compared with tissues from timolol-treated Kyoto-Wistar (WKY) control rats. The normotensive SHR aorta also showed significant responsiveness to H+ and to high Ca2+ concentrations without previously depolarizing the tissue with high K+. These observations suggest that the increased reactivity seen in vascular smooth muscle from this animal does not develop secondary to elevated peripheral resistance and subsequent hypertrophy, and that the initiation of hypertension in this animal may be related to a membrane defect and (or) cellular defect which results in a facilitation of Ca2+ availability for the contractile proteins of the SHR vascular smooth muscle cell.

Animals↗

PubMed1981

Timolol treatment in the irritable bowel syndrome.

The overall effect of the beta-blocker timolol maleate was not significantly different from placebo in patients with the irritable bowel syndrome on a high fibre diet. However, all 3 symptom-free patients were on timolol maleate. If beta-blockers have a major role to play in the treatment of the irritable bowel syndrome it must be through a central rather than a peripheral effect.

Clinical Trials as Topic↗

PubMed1991

Effect of timolol on human retinal, choroidal and optic nerve head circulation.

In a double-masked, randomized, placebo-controlled study, we evaluated the effect of topical timolol maleate 0.5% on the retinal, choroidal, and optic nerve head circulation in 5 healthy volunteer subjects. Changes in the pulsatile component of choroidal blood flow (PCBF) were determined from measurements of the ocular pulse wave. Changes in the retinal arterial blood flow rate (RBF) and optic nerve head capillary blood speed (CBS) were determined by laser Doppler velocimetry and monochromatic photography. In timolol-treated eyes, PCBF decreased by 32 +/- 12% (p = 0.0007). Changes in RBF and CBS were not statistically significant. In the contralateral placebo-treated eyes, PCBF decreased by 15 +/- 8% (p = 0.006) and RBF increased by 18 +/- 10% (p = 0.002). The change in CBS was not statistically significant.

Administration, Topical↗

PubMed1995

Pattern electroretinogram in treated ocular hypertension: a cross-sectional study after timolol maleate therapy.

To investigate pattern electroretinogram changes in treated ocular hypertension, we evaluated pattern electroretinogram recordings of 48 hypertensive eyes following an 8-month timolol maleate therapy. During treatment, 27 of 48 eyes had normalized intraocular pressures (15-18 mm Hg), while 21 retained elevated values (21-25 mm Hg). Twenty-eight eyes with untreated hypertension (22-25 mm Hg) lasting at least 8 months, as well as 32 untreated, normotensive eyes served as controls. When compared to untreated normotensive controls, timolol-treated eyes with either elevated or normalized intraocular pressures showed reductions in the mean electroretinographic amplitudes. However, these amplitude reductions were substantially greater in treated eyes with elevated pressures as compared to those with normalized ones. Untreated hypertensive controls showed pattern electroretinogram reductions, with respect to normal values, that were comparable to those of treated hypertensive eyes, but larger than those of treated normotensive ones. These results indicate that, in treated ocular hypertension, pattern electroretinogram losses tend to be associated with moderately increased intraocular pressures in the range of 21-25 mm Hg. Electroretinographic abnormalities may be, at least in part, prevented only by lowering intraocular pressure into a normal range.

Adult↗

PubMed1994

Topical atropine and timolol therapy in failed retinal detachment surgery.

We conducted a double-blind randomized prospective study to evaluate the efficacy of topical timolol alone and topical timolol and atropine combined in cases of operated failed retinal detachment surgery cases in which no apparent open break explained the surgical failure. In both groups with and without proliferative vitreoretinopathy no statistically significant difference in retinal reattachment was found.

Administration, Topical↗

PubMed1984

The effects of timolol maleate on subjective and physiological components of air travel phobia.

Twenty-one monophobic patients with moderately severe fear of flying were exposed to two 40 minute challenge flights after taking either Timolol 20 mg/day or placebo. Heart rate, blood pressure, subjective ratings of anxiety, fear and palpitation and Hamilton Anxiety Scale ratings were made at the predetermined assessment intervals. Post-treatment global ratings of improvement were provided by patients and the attending psychiatrist. Results showed that heart rate significantly increased from baseline with placebo while Timolol successfully inhibited tachycardia during the challenge flights. Subjective ratings of anxiety, fear and palpitations did not show any drug group differences. These variables, however, showed a non-significant decrease from outgoing to return flight assessments after an initial significant increase from baseline scores. Hamilton Anxiety Scale ratings showed a significant decrease from baseline to post-treatment assessments, irrespective of drug group. Global improvement ratings revealed no significant differences between drug groups. Overall ratings by the psychiatrist were generally more positive than patients' ratings, with the difference between the two sources of assessment reaching significance only in the placebo group. Disregarding group membership, heart rate was positively and significantly correlated with subjective ratings of fear, but not with palpitations or ratings of overall anxiety.

Adolescent↗

PubMedDate not supplied

Color Doppler imaging study in patients with primary open-angle glaucoma treated with timolol 0.5% and carteolol 2%.

PURPOSE: To evaluate with color Doppler imaging (CDI), in patients with primary open-angle glaucoma (PDAG), the possible influence on ocular hemodynamics of a beta-blocking agent with intrinsic sympathomimetic acitivity (carteolol 2%) compared to a beta-blocker agent without this activity. METHODS: A study was carried out on 20 patients, with bilateral POaG, intraocular pressure (IOP) < or = 20 mmHg, all treated twice a day with timolol maleate 0.5% ophthalmic solution. The visual field was evaluated (Octopus 2000 perimeter, G1 program) examining the mean sensitivity (MS) and the mean defect (MD). CDI was carried out to evaluate the resistance index of the internal carotid artery (ICA), the ophthalmic artery (OA), the central retinal artery (CRA), and the short posterior ciliary arteries (SPCA). After these examinations, the therapy was changed to carteolol 2% twice a day. After six months of treatment the examinations were repeated. The data were analysed statistically using Student's t test. RESULTS: The mean intraocular pressure during treatment with timolol 0.5% was 16.7 +/- 1.67 mmHg and 16.33 +/- 1.72 mmHg after treatment with carteolol 2%, the difference not being significant (p=0.494). After six months of treatment with carteolol 2% the MS increased significantly from 22.4 +/- 2.5 dB to 24.1 +/- 1.8 dB (p=0.018), and the mean defect (MD) fell from 5.3 +/- 0.8 dB to 4.7 +/- 0.6 dB (p=0.011). There was no significant difference in the resistance index of the CA, the OA and the CRA with the two treatments, whereas the resistance index of the SPCA dropped significantly, from 0.80 +/- 0.05 to 0.77 +/- 0.02 (p = 0.017). CONCLUSIONS: CDI did not show significant differences in the resistance indexes of the internal CA, the OA, and the CRA after treatment with carteolol 2% but the resistance index of the SPCA was significantly reduced. Carteolol 2% induced significant changes in the perimetric indexes examined, with an increase in MS and a decrease in MD. These findings suggest that the intrinsic sympathomimetic activity of carteolol may reduce peripheral vascular resistance of the SCA, thus improving perfusion of the optic nerve head, with a protective effect on visual function.

Adrenergic beta-Antagonists↗

PubMedDate not supplied

Influence of carteolol and timolol on IOP an visual fields in glaucoma: a multi-center, double-masked, prospective study.

The influences of Carteolol and Timolol eye drops on intraocular pressure (IOP) and visual fields were compared in a multi-center, double-masked, prospective study. Two-hundred and forty eyes of 120 patients were initially included in the study, and 142 eyes of 72 patients fulfilled all the criteria for final statistical analysis. Both drugs significantly reduced IOP. The visual fields in both treatment groups did not change during one year of treatment. In both groups some patients improved slightly, and others deteriorated slightly. This indicates that locally applied beta-blockers may efficiently stop further progression of visual field defects in cases with increased IOP and early visual field damage. There was no difference between Carteolol and Timolol in this regard. The side effects were minimal, and there were no differences in their frequency or intensity in the two treatment groups.

Adolescent↗